NASDAQ:TOCATocagen Stock Price, Forecast & News

Tocagen's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TOCA stock has decreased by 18.7% and is now trading at $1.26. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tocagen.

Tocagen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tocagen.

Tocagen Inc (NASDAQ:TOCA) issued its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative return on equity of 327.74%. View Tocagen's earnings history.

7 Wall Street analysts have issued twelve-month target prices for Tocagen's stock. Their forecasts range from $1.00 to $3.32. On average, they expect Tocagen's share price to reach $1.77 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price. View analysts' price targets for Tocagen.

News coverage about TOCA stock has trended negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tocagen earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Tocagen.

Some companies that are related to Tocagen include Revance Therapeutics (RVNC), Akcea Therapeutics (AKCA), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Kiniksa Pharmaceuticals (KNSA), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Amneal Pharmaceuticals (AMRX), Arvinas (ARVN), Tricida (TCDA), Theravance Biopharma (TBPH), Odonate Therapeutics (ODT), Rocket Pharmaceuticals (RCKT) and Supernus Pharmaceuticals (SUPN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Amarin (AMRN), VBI Vaccines (VBIV), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX) and Catalyst Pharmaceuticals (CPRX).

(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $1.26.

Tocagen has a market capitalization of $30.14 million and generates $40,000.00 in revenue each year. The company earns $-63,520,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Tocagen employs 77 workers across the globe.

The official website for Tocagen is www.tocagen.com.

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]dvisors.com.